Bromhexine, orciprenaline (Benylin Chesty, Flemeze Bronchodilatory)
Bromhexine, orciprenaline
Johnson & Johnson (Pty) Ltd û East London
Every registration of this product has been cancelled.
Registration
- Applicant
- Johnson & Johnson (Pty) Ltd û East London
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Benylin chesty EACH 5 ml CONTAINS BROMHEXINE HYDROCHLORIDE A 4 mg ORCIPRENALINE SULPHATE A 5 mg | Not listed | 29028829/10.1/0288 | Cancelled | Not determined | None |
| Flemeze bronchodilatory syrup EACH 5 ml LIQUID CONTAINS BROMHEXINE HYDROCHLORIDE A 4 mg ORCIPRENALINE SULPHATE A 5 mg | Syrup | 29028929/10.1/0289 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Metaproterenol
- when intended for the prevention or delay of labour, and preparations thereof for injection. (S2, S3)
Consolidated Schedules 06 July 2026, lines 7079 to 7080
S3: Metaproterenol
- when contained in respirator solutions.
Consolidated Schedules 06 July 2026, line 3936
S2: Bromhexine
Consolidated Schedules 06 July 2026, line 1684
S2: Metaproterenol
- when contained in respirator solutions; (S3) and
- when intended for injection. (S4)
- when intended for the prevention or delay of labour, (S4)
Consolidated Schedules 06 July 2026, lines 2327 to 2333
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.